INTRODUCTION
Plasma cell myeloma (PCM) is a fatal proliferation of neoplastic plasma cells producing monoclonal immunoglobulins. At the time of diagnosis, extramedullary lesions are found in approximately 7% of patients, whereas another 6% may develop such lesions later in their disease course. 1 However, the central nervous system (CNS) is a rare location for extramedullary involvement, found in approximately 1% of PCM patients. 2 The translocation, t(14;20)(q32;q11) involving IGH and MAFB gene loci, is a rare chromosomal abnormality in PCM. Patients with this translocation usually have a poor prognosis and may be resistant to novel agents for PCM. [3] [4] [5] [6] However, the clinical course of t(14;20)-positive PCM patients has not been well clarified due to its rarity. In this report, we present a t(14;20)-positive PCM patient who responded well to a proteasome inhibitor, bortezomib, but later developed tumor relapse in the CNS and died of the disease.
CASE REPORT
A 63-year-old Japanese female patient with an unremarkable medical history presented to our hospital with the complaint of general fatigue persisting for three months. No hepatosplenomegaly or lymphadenopathy was identified and the physical examination was otherwise unremarkable. She was found to have localized pneumonia, mild anemia, and moderate hyperproteinemia. The laboratory data at the initial presentation are shown in Table 1 . Serum electrophoresis revealed a homogeneous peak in the gamma fraction, which was identified as the IgA-lambda type by immunofixation assay. The patient also had a high IgA concentration (3665 mg/dL; reference range, 90-450 mg/dL), and reduced concentrations of IgM (26 mg/dL; 60-250 mg/dL) and IgG (363 mg/dL; 800-1800 mg/dL). Serum-free light chain analysis revealed increased lambda-type (529 mg/L; 5.7-26.3 mg/ L) and decreased kappa-type (2.6 mg/L; 3.3-19.4 mg/L) levels. The β2-microglobulin level was high (7.9 mg/L; reference range; 1-1.9 mg/L) and the serum calcium level was normal (8.9 mg/dL; 8.7-10.3 mg/dL). Radiological exami-
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DISCUSSION
A molecular cytogenetic classification of PCM has been proposed by the International Myeloma Working Group, and the genetic categories serve as major indicators of prognosis and form the basis for risk stratification. 10 Seven recurrent oncogenes are associated with the IGH gene on 14q32: CCND1 on 11q13, MAF on 16q23, FGFR3/NSD2 on 4p16.3, CCND3 on 6p21, MAFB on 20q11, MAFA on 8q24, and CCND2 on 12p13. 10, 11 Among these oncogenes, t(14;20)/ IGH-MAFB is one of the most infrequent translocations in primary PCM cases, accounting for less than 2%. [12] [13] [14] Another research group estimated the frequency to be 0.9%. 3 t(14;20) was reported to be associated with a poor prognosis. PCM patients with t(14;20) often develop primary plasma cell leukemia and extramedullary disease. 4 These t(14;20)positive PCM features are consistent with those in our patient, who exhibited atypical plasma cells in the peripheral blood at diagnosis and tumor relapse in the CNS.
Proteasome inhibitor-based regimens may not improve survival for patients with t(14;20). 15, 16 The molecular mechanism of this resistance has not been well clarified. Recently, Qiang et al. reported that MAFB protein provides PCM cells with an intrinsic resistance to proteasome inhibitors via the abrogation of proteasome inhibitor-induced apoptosis and activation of the caspase family. 6 Table 1 . Laboratory findings on admission ↑denotes a level above the upper limit of the reference range, and ↓ denotes a level below the lower limit of the reference range.
The prognosis of these patients is poor. Jurczyszyn et al.
carried out a multicenter retrospective study that included 172 adult patients with CNS PCM (22% were diagnosed with CNS involvement at the time of the initial PCM diagnosis and 78% at relapse/progression). 17 Although the therapies targeted the CNS in most patients, the median overall survival from the onset of CNS involvement was 7 months. They also reported chromosomal abnormalities: del13q in 39% of the PCM cases, del17p in 23%, t(4;14) in 12%, and t (11;14) in 7%. 17 It is currently unknown whether t(14;20) is specifically associated with CNS involvement. However, considering the clinical aggressiveness of t(14;20)-positive PCM, the CNS involvement in our patient may have been associated with t (14;20) . In PCM patients with CNS involvement, the efficacy of systemic treatment or the use of novel agents, including proteasome inhibitors and immunomodulatory drugs, is controversial. Katodritou et al. reported that these novel agents did not improve the post-CNS-PCM survival in a study involving 2,408 newly diagnosed symptomatic PCM patients. 18 On the other hand, Chen et al. reported that long-term survival in CNS PCM can be achieved by combination therapy including multi-dosing intrathecal chemotherapy, radiation, and immunomodulatory agents. 19 For our patient, the administration CPM, high-dose cyclophosphamide; DEX, high-dose dexamethasone; iPAD, bortezomib, doxorubicin, and dexamethasone; Bd, bortezomib and dexamethasone; WBRT, whole-brain radiation therapy; RT, radiation therapy; Hb, hemoglobin; RC, red blood cell transfusion; WBC, white blood cell; BMPC, bone marrow plasma cell; Plt, platelet; PC, platelet transfusion; CNS, central nervous system; FLC, serum free light chain. WBRT1, RT to the whole brain; RT2, to the right pelvis and the right thigh; RT3, to the left thigh, RT4, to the right periscapular and upper arm; RT5, to the right calf; RT6, to the right upper arm; RT7, to the right chest wall; and RT8, to the left calf. of immunomodulatory agents (lenalidomide) was not sufficient and its efficacy for CNS tumors was not evaluated. Based on the autopsy findings in our case, the CNS was tumor free, suggesting that radiotherapy was effective for local control of PCM involving the CNS. In summary, we reported a rare t(14;20)-positive PCM patient in whom tumor relapse in the CNS developed six months after complete remission was achieved by proteasome inhibitor treatment. The accumulation of more cases is needed to establish the most appropriate therapeutic regimens against t(14;20)-positive PCM.
Clinical course

